How many investments has V-Bio Ventures made?

V-Bio Ventures has 22 tracked investments.

What stage does V-Bio Ventures invest at?

V-Bio Ventures invests at the Seed, Series A, Series B, Growth stages.

What is V-Bio Ventures's typical check size?

V-Bio Ventures typically writes checks of $270K – $2.2M.

What sectors does V-Bio Ventures focus on?

V-Bio Ventures focuses on AgTech, Biotech, Healthtech, Longevity, Medical Devices.

Where is V-Bio Ventures located?

V-Bio Ventures is headquartered in Ghent, BE.

Who does V-Bio Ventures co-invest with?

V-Bio Ventures most often shares deals with PMV, Fund+, Kurma Partners, among 43 tracked co-investors.

V-Bio Ventures

Venture capital

Ghent · Seed–Growth · 13 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into V-Bio Ventures

1,210 people in our graph share verified history with the V-Bio Ventures team — schools, employers, funds. One of them is your warm intro.

Sally Appletonunlockedknows Christina Takke · together at ABN AMRO Capital (overlapped)

knows the team · via De Haagse Hogeschool / The Hague University of Applied Sciences

×2knows the team · via KU Leuven

×3knows the team · via Imperial College London

knows the team · via VIB

×2knows the team · via Vlerick Business School

✨ Fox Verdict

Investment thesis

V-Bio Ventures backs private life science companies with differentiated technologies that address unmet needs and offer high societal or environmental impact potential. The fund focuses on therapeutics, spanning both drug discovery and drug development, and co-creates startups in addition to investing in early- to mid-stage ventures. It maintains a preferred relationship with the Belgian research institute VIB, building some companies on VIB-derived innovation, while also sourcing deals from other research institutes, entrepreneurial initiatives, and corporate spin-outs. The firm concentrates geographically on Europe and offers more than capital through its network and sector expertise.

Invests inAgTech Biotech Healthtech Longevity Medical Devices Brussels Europe

Source: firm website, verified Aug 7, 2026.

Stage

Seed–Growth

Check

$270K – $2.2M

Ghent, BE

Instruments

Equity

Founded

2015

AUM

$200.9M

Tracked investments

Team · 13 people

from the firm's website & public directories

Christina Takke· Managing Partner· Amsterdam, North Holland, Netherlandsin

Co-founded V-Bio Ventures in 2015 and serves as Managing Partner. She previously spent over 15 years in European venture capital, most recently as a partner at Forbion Capital Partners, and holds a PhD in developmental biology.

c•••@v-bio.venturesreveal

Shelley Margetson· Managing Partner· Ghent, Flemish Region, Belgiumin

Joined V-Bio Ventures in December 2020 as Managing Partner. She spent over 20 years in finance and executive roles across European biotech, including CFO of Merus and CEO of Gadeta.

s•••@v-bio.venturesreveal

Willem Broekaert· Managing Partner· Ghent, Flemish Region, Belgiumin

Co-founded V-Bio Ventures in 2015 and serves as Managing Partner. He spent over 15 years in VC-backed life sciences companies as entrepreneur and executive, including founding Fugeia NV and serving as VP R&D of CropDesign NV.

w•••@v-bio.venturesreveal

Katja Rosenkranz· Partner· Ghent, Flemish Region, Belgiumin

Joined V-Bio Ventures in 2016. She brings over 12 years in life science venture, having worked at Polytechnos Venture-Partners, Advitos and Ascenion, and holds a PhD in biochemistry plus an Executive MBA.

k•••@v-bio.venturesreveal

Ward Capoen· Partner· Ghent, Flemish Region, Belgiumin

Joined V-Bio Ventures in 2016 as Partner. He holds a PhD in molecular biology, researched at VIB/UGent, John Innes Centre and Harvard Medical School, and previously worked as a senior biotech analyst at Candriam Investors Group.

w•••@v-bio.venturesreveal

Aurelie Nowack· Principal· Singaporein

a•••@v-bio.venturesreveal

Mathias Falcenberg· Venture Partner· Frankfurt Rhine-Main Metropolitan Areain

Joined V-Bio Ventures as Venture Partner in February 2025. His experience spans healthcare across entrepreneur, investor and corporate roles, including external innovation work at Merck KGaA and venture capital experience at Forbion.

Dr. Loïc Laplanche· Chief Operating Officer (COO), BIODOL Therapeutics

Dr. Loïc Laplanche, Ph.D., has more than 25 years of experience in non-clinical and translational sciences across discovery, preclinical, and clinical development in global pharmaceutical companies. He most recently held the role of Senior Scientific Director at AbbVie, where he led DMPK and regulated bioanalysis functions and contributed to non-clinical portfolio strategy in neuroscience, immunology, and oncology. He previously worked as a researcher at Sanofi-Aventis and led projects in several EU-IMI consortia, with expertise in non-clinical development and quantitative and translational pharmacology.

Dr. Marie-Laurence Gourlay-Chu· Chief Medical Officer

Medical doctor with over 25 years of experience in clinical development, pharmacovigilance, and medical affairs across biotech and pharma. Previously served as CMO at PPRS SAS and held leadership roles at Genethon, Ipsen, AstraZeneca, and the French Health Products Safety Agency, with therapeutic focus in immunology, CNS, and rare diseases.

Martin Solleveld· Finance Manager· The Randstad, Netherlandsin

Involved with V-Bio Ventures since its 2015 inception as Finance Manager. He has extensive financial management experience in venture capital and biotech and has been an independent financial consultant since 2004.

Tom Schwarz· Strategic Advisory Board Memberin

Member of V-Bio Ventures' strategic advisory board with over 20 years in biotech and medtech venture capital. He co-founded Life Sciences Partners and Innovation Industries and previously co-founded and led U-Gene Research.

Charles Margarit· Associate

c•••@v-bio.venturesreveal

Dennis Pedri· Analyst

d•••@v-bio.venturesreveal

What they invest in

from 20 of 22 portfolio companies

Biotech ×19Healthtech ×10Deep Tech ×9Medical Devices ×9AI & Machine Learning ×4AgTech ×3Digital Health ×3Longevity ×2

HQs:Belgium×7France×3United States×2Italy×1Netherlands×1

Who they back

founder profiles across 11 portfolio companies

45%

solo founders

5 of 11 mapped founding teams

31%

repeat founders

of 13 founders with career history

Founding team size:solo founder×52 founders×33 founders×14+ founders×2

Where their founders studiedfrom 10 founders with education data

Ghent University ×2

What their founders studiedfrom 11 founders with field-of-study data

Life Sciences ×6Engineering ×2Medicine ×2

Where their founders worked beforefrom 13 founders with career history

VIB ×4European Research Council (ERC) ×2Sanofi ×2

Investments · 22 tracked

founders shown can be your intro path

By year:2024 · 1 2023 · 1 2022 · 1 2020 · 14 dated

ATB Therapeuticsatbtherapeutics.com in 𝕏✓ verified

ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments.

BiotechHealthtechMedical Devices

Dr. Mark Throsby(Chief Executive Officer)

Co-investorsMRL Ventures Fund VIVES Partners EQT Life Sciences Sambrinvest Wallonie Entreprendre

Corteriapharmacorteriapharma.com in✓ verified

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

Philip Janiakin Marie-Laure Ozoux inRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin

Co-investorsFountain Healthcare Partners Jeito Capital Kurma Partners OrbiMed Omnes Capital Invivo Capital Partners +1 more

Exevirexevir.com in✓ verified

ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations.

BiotechDeep TechDigital HealthHealthtechMedical DevicesGhent, BE

Xavier Saelens(Scientific Founder)Nico Callewaert(Scientific Founder)inMike Garrett(Chief Executive Officer)

Co-investorsSambrinvest UCB Ventures VIB Fund+VIVES Partners

Protealisprotealis.com inJan 2024✓ verified

Protealis breeds legume crops such as soybeans and yellow peas and develops proprietary seed coatings with nitrogen-fixing bacteria adapted to the European climate.

AgTechBiotechFoodTechGent, BE

Benjamin Laga(Co-founder & CEO)inJonas Aper(Co-founder & Director of Breeding)in

Co-investorsAgri Investment Fund Innovation Industries Korys Estari Group VIB PMV +1 more

Sibyllasibyllabiotech.it in 𝕏Oct 2022✓ verified

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.

AI & Machine LearningBiotechDeep TechTrento, IT

Emiliano Biasini(Co-founder)in Pietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)in Maria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)

Co-investors3B Future Health Fund CDP Venture Capital Seroba Life Sciences Vertis SGR VI Partners Claris Ventures +1 more

Agomab Therapeuticsagomab.com in

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need.

BiotechHealthtechMedical DevicesAntwerp, BE

Tim Knotnerus(Chief Executive Officer)in

Co-investorsEQT Life Sciences AdBio partners Andera Partners Asabys Partners Canaan Partners Pontifax Venture Capital +1 more

Anetaaneta.companyMay 2023

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPebblebed Andera Partners BGV Forbion Fountain Healthcare Partners HTGF +2 more

Animabanimab.com

Animab develops proprietary antibodies that mimic natural intestinal protection mechanisms to safeguard piglets' health during post-weaning, a critical period in livestock production.

AgTechBiotechDeep TechHealthtechGhent, BE

Vikram Virdi(Chief Science Officer & Scientific Co-Founder)inAnn DepickerNico CallewaertEric CoxHenri De Greve Alain Wille(CEO)in

Co-investorsAgri Investment Fund Seventure Partners PMV Qbic Fund

Apheaaphea.bio

Aphea.Bio develops bioinsecticides targeting sap-sucking insects that damage crops, in partnership with Bayer to accelerate their development.

AgTechBiotech

Isabel Vercauterenin

Co-investorsAstanor Ventures European Circular Bioeconomy Fund Innovation Industries PMV AIF Bill & Melinda Gates Foundation +1 more

Arctherapeuticsarctherapeutics.bio

Arc Therapeutics is a stealth-stage biopharmaceutical company developing medicines for central nervous system (CNS) conditions with high unmet medical needs.

BiotechHealthtech

Co-investors+ND Capital

Astrivaxastrivax.com

Astrivax Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies to treat virus-driven cancers, particularly HPV16-associated cancers like cervical and head and neck cancer.

BiotechDigital HealthHealthtechMedical Devices

Hanne Callewaert(Founder)in

Co-investorsFund+Korys PMV

Augustine Therapeuticsaugustinetx.com in

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.

BiotechMedical Devices

Co-investorsAdBio partners Jeito Capital Novo Holdings PMV Asabys Partners Newton Biocapital

Avidicureavidicure.com

Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases.

AI & Machine LearningBiotech

Robert Friesen(Founder)in

Co-investorsBioGeneration Ventures EQT Life Sciences BOM Curie Capital Kurma Partners

Biodolbiodol.eu

Biodol Therapeutics is a biotech company developing proprietary FLT3 inhibitors (BDT compounds) at the preclinical stage to treat neuropathic and chronic pain, including opioid-combination indications.

BiotechMedical DevicesMontpellier, FR

Coave Therapeuticscoavetx.com in

Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.

BiotechDeep TechHealthtechMedical DevicesParis, FR

Co-investorsFund+Kurma Partners Seroba Life Sciences Bpifrance Invus Novo Holdings +1 more

Confo Therapeuticsconfotherapeutics.com in

VIB is a non-profit research institute focused on strategic basic research in life sciences, operating in partnership with five Flemish universities.

BiotechDeep TechMedical DevicesGhent, BE

Jan Steyaert(Founder (Scientific))inCedric Ververken(CEO)in

Co-investorsCapricorn Venture Partners Fund+PMV Quest for Growth BioGeneration Ventures

Flindrflindrtx.com in 𝕏

Flindr is a biotech company developing small molecule inhibitors for cancer treatment using its ImmunoGram Drug Discovery Engine to identify novel therapeutic targets in cancer and immune cells.

AI & Machine LearningBiotechDeep TechHealthtechGhent, BE

Maarten Ligtenberg(Founder / Chief Executive Officer)Prof. Daniel Peeper(Founder)Prof. Christian Blank(Founder)

Co-investorsBOM

Muna Therapeuticsmunatherapeutics.com in 𝕏

Muna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.

BiotechDeep TechHealthtechLongevity

Rita Balice-Gordon(Founder)in Joachim Vilstrup(Head of Protein Chemistry and Structural Biology; scientific co-founder)in Michel Detheux(Chief Executive Officer & Board Director)inAnders Hinsby(Chief Operating Officer)in Niels Plath(Chief Scientific Officer)in Jakob Busch-Petersen(Chief Development Officer)in

Co-investorsDroia Ventures Sanofi Ventures Sofinnova Partners

Orionis Biosciencesorionisbio.com in 𝕏

Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses.

BiotechDeep TechNewton, US

Nikolai Kley(Founder)inNikolai Kley, Ph.D.(Executive Officer, Director)

BoardGriet Vanpoucke, Ph.D.(Director)Steven R. Gullans, Ph.D.(Director)

Co-investorsExcel Venture Management Solari Capital Solasta Ventures Wessel Management

RootWaverootwave.comJan 2020

Develops electric weed control technology using high-frequency AC to destroy weeds to the roots, as an alternative to chemical herbicides.

Co-investorsAgri Investment Fund Oxford Investment Opportunity Network (OION)The Yield Lab The Yield Lab Europe

Step Pharmastep-ph.com in

Step Pharma develops oral cancer drugs that inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1), with its lead therapeutic dencatistat in clinical development for lymphoma, solid tumors, and essential thrombocythaemia.

BiotechDeep TechMedical DevicesSaint-Genis-Pouilly, FR

Alain Fischer(Founding Scientist)

Co-investorsHadean Ventures Kurma Partners Bpifrance Pontifax Venture Capital Sunstone Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

PRECIRIX NV

Portfolio news

latest coverage across their companies

Agomab proposes two new board members, sets shareholder vote By Investing.com

Agomab Therapeutics · investing.com · Aug 10, 2026

AgriFood Signals: EIF commits $29m to Irish agrifoodtech, Aphea.Bio and Bayer team up, GLP-1 pills

Aphea · agfundernews.com · Jun 11, 2026

Coave Therapeutics Launches CNS-Targeted Gene Therapy Capsid Developed with Proprietary Platform | BioPharm International

Coave Therapeutics · biopharminternational.com · May 26, 2026

Protealis Expands European Footprint with New Soy Varieties

Protealis · igrownews.com · Mar 23, 2026

Muna Therapeutics Awarded $1 Million Alzheimer's Association Grant to Advance Clinical Development of Novel Oral TREM2 Agonist MNA-001 for Alzheimer's

Muna Therapeutics · prnewswire.com · Jan 8, 2026

Step Pharma announces completion of €38 million Series C financing - BioSpace

Step Pharma · biospace.com · Oct 16, 2025

Avidicure is included in the "Biotech Financing" report in Nature Biotechnology - Avidicure DEV

Avidicure · avidicure.com · Jun 27, 2025

New AG International RootWave raises $15m to scale high-tech weed control - New AG International

RootWave · newaginternational.com · Jun 23, 2025

Frequently asked questions

How many investments has V-Bio Ventures made?: V-Bio Ventures has 22 tracked investments.
What stage does V-Bio Ventures invest at?: V-Bio Ventures invests at the Seed, Series A, Series B, Growth stages.
What is V-Bio Ventures's typical check size?: V-Bio Ventures typically writes checks of $270K – $2.2M.
What sectors does V-Bio Ventures focus on?: V-Bio Ventures focuses on AgTech, Biotech, Healthtech, Longevity, Medical Devices.
Where is V-Bio Ventures located?: V-Bio Ventures is headquartered in Ghent, BE.
Who does V-Bio Ventures co-invest with?: V-Bio Ventures most often shares deals with PMV, Fund+, Kurma Partners, among 43 tracked co-investors.

Images

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M

LIFTT

LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.

AgeTech Capital

AgeTech Capital is a purpose-driven private market investment firm backing technology solutions that support healthier, wealthier and more fulfilling aging.